Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Nuvalent ( (NUVL) ).
On November 17, 2025, Nuvalent announced positive topline pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from their ALKOVE-1 Phase 1/2 clinical trial. The data showed promising efficacy and a well-tolerated safety profile, with notable response rates and duration of response in patients with prior treatments. The company plans to discuss these findings with the FDA and present detailed results at a future medical meeting, indicating potential advancements in treatment options for this patient population.
The most recent analyst rating on (NUVL) stock is a Buy with a $126.00 price target. To see the full list of analyst forecasts on Nuvalent stock, see the NUVL Stock Forecast page.
Spark’s Take on NUVL Stock
According to Spark, TipRanks’ AI Analyst, NUVL is a Neutral.
Nuvalent’s overall score reflects the typical high-risk, high-reward nature of early-stage biotech firms. Strengths include a solid cash position and no debt, while significant risks arise from the lack of revenue and dependency on external financing. Technical indicators suggest positive short-term momentum, but overbought conditions may present challenges. Valuation metrics are not favorable due to negative earnings.
To see Spark’s full report on NUVL stock, click here.
More about Nuvalent
Nuvalent, Inc. operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. Their primary product in development is neladalkib, an investigational ALK-selective inhibitor aimed at treating advanced ALK-positive non-small cell lung cancer (NSCLC).
Average Trading Volume: 456,284
Technical Sentiment Signal: Buy
Current Market Cap: $7.02B
Find detailed analytics on NUVL stock on TipRanks’ Stock Analysis page.